Role of Atorvastatin for treatment of Central Retinal Vein Occlusion and long term prognosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN61985307

Enrollment

Registered

2007-07-23

Start date

2007-05-10

Completion date

Unknown

Last updated

2018-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central Retinal Vein Occlusion Eye Diseases Disorders of choroid and retina

Interventions

Intervention treatment: Duration of atorvastatin planned to be given is for two months. Dosage is to be 10 mg per day, given once in a day, orally. Control treatment: Treatment as usual. Both group

Eligibility

Inclusion criteria

Inclusion criteria: Patients with: 1. Central Retinal Vein Occlusion (CRVO) of more than one day duration 2. No other ophthalmic pathologies 3. No contraindication to atorvastatin 4. No prior use of statins

Exclusion criteria

Exclusion criteria: Patients with CRVO of less than one day duration are treated conventionally and those who have other ophthalmic pathologies or patients who have been on atorvastatin or any other statins earlier are not included in any groups.

Design outcomes

Primary

Measure	Time frame
1. Visual acuity 2. Tortuosity of retinal veins	—

Secondary

Measure	Time frame
Recurrence of Central Retinal Vein Occlusion	—

Countries

India

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026